DBV Technologies

Autolus Therapeutics Announces Changes to its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Cubist Pharmaceuticals, DBV Technologies, MB, Alnylam Pharmaceuticals, Harvard Medical School, University of Cambridge, Faculty, Imperial College London, Development, GSK plc, Biologics license application, Hematology, Patient, ALL, Merck, Bristol Myers Squibb, Marketing, Biogen, Doctor of Philosophy, Bates College, Oxford Biomedica, Sarepta Therapeutics, Pharmaceutical medicine, Therapy, Swedish Orphan Biovitrum, Royal college, FDA, BLA, Autoimmunity, Economics, Food, Pharmaceutical industry

John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.

Key Points: 
  • John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.
  • We wish John much success with his new projects,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
  • He is currently a director of Alnylam Pharmaceuticals and chair of Dunad Therapeutics and Gulf of Maine Research Institute.
  • Mr. Bonney has served as a director with many companies previously including Celgene, Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals.

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

Retrieved on: 
Friday, March 8, 2024
DBV Technologies, Annual report, File, Form, URD, Food, DBV, Pierre Brossolette

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
  • These documents can be accessed on the Investors section of the Company's website at www.dbv-technologies.com .
  • In addition, the URD is available on the AMF’s website at www.amf-france.org and the Form 10-K is available on the SEC’s website at www.sec.gov .
  • Printed copies of both documents are available, free of charge, at the Company’s headquarters and registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France.

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 7, 2024
Vitesse, European Commission, Marketing, DBV Technologies, Blas, FDA, Form 10-K, File, Research and development, Language, Sale, BLA, Toddler, American College, Form, Financial statement, Safety, American depositary receipt, GAAP, Good news, Immunology, Administration, Net, Food, Asthma, DBV, Initiate, Development, Bank statement, Agreement, Editorial, Cryptocurrency

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.
  • Published EPITOPE results in the New England Journal of Medicine with an accompanying editorial, entitled, Good News for Toddlers with Peanut Allergy.
  • ET to discuss full year 2023 financial results and provide a business update.
  • The conference call may be accessed by dialing:
    A webcast of the call will also be available under "Events" in the Investors section of the DBV Technologies website: https://dbv-technologies.com/investor-overview/events .

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

Retrieved on: 
Monday, March 4, 2024
Food, DBV Technologies, DBV

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

Key Points: 
  • DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
    DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m.
  • ET to review full year 2023 financial results and provide a business update.
  • Interested participants may access this call via the below teleconferencing numbers and reference the DBV Technologies call:
    A live webcast of the call will also be available under "Events" in the Investors section of the Company’s website: https://dbv-technologies.com/investor-overview/events .
  • A replay of the presentation will also be available on DBV’s website after the event.

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Retrieved on: 
Tuesday, February 20, 2024
PEOPLE, BAT, DBV Technologies, AAAAI, Immunotherapy, Safety, EST, Peanut allergy, Toddler, FIT, Longitudinal, Convention center, D.C, Associate, Walter, Patient, Clinical trial, Pediatrics, Asthma, Food, Diagnosis, DBV, Ageing, American Academy, Pharmaceutical industry

DBV is sponsoring a non-CME Product Theater titled “Importance of Early Intervention for Peanut Allergy.” Professors Hugh Sampson, M.D.

Key Points: 
  • DBV is sponsoring a non-CME Product Theater titled “Importance of Early Intervention for Peanut Allergy.” Professors Hugh Sampson, M.D.
  • DBV will host a booth (#567) in the AAAAI exhibit hall where attendees can learn more about epicutaneous immunotherapy with Viaskin, including our ongoing clinical trials in peanut-allergic children.
  • Chief Medical Officer at DBV Technologies.
  • “DBV, is committed to generating robust, long-term safety data with Viaskin Peanut to aid in future shared decision-making.

InBrain Pharma Announces the Appointment of Dr Véronique Foutel as CEO

Retrieved on: 
Tuesday, February 27, 2024
Mental Health, Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, DBV Technologies, Hospital, Pharmacy, CHU, Dopamine, Growth, Neurological disorder, DSM-IV codes, Entrepreneurship, Pharmaceutical industry, Prevalence, Parkinson's disease, Headquarters, Medicine, Patient, Disease, CSO, Brain

InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.

Key Points: 
  • InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.
  • Dr. Matthieu Fisichella, co-founder, and current CEO since 2018, will remain highly committed to InBrain Pharma and become Chief Science Officer.
  • ," says Véronique Foutel, CEO of InBrain Pharma.
  • "I am delighted to hand over the reins to Véronique, whose appointment comes at a critical time for InBrain Pharma.

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Retrieved on: 
Tuesday, January 16, 2024
ODDO BHF, DBV, NATIXIS, DBV Technologies, Cryptocurrency

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with NATIXIS ODDO BHF.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with NATIXIS ODDO BHF.
  • Under the liquidity contract between DBV Technologies and NATIXIS ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2023:
    When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:
    Over the period from July 1, 2023, to December 31, 2023, the following transactions were executed:
    376,978 shares and € 911,734.76 on purchases,
    303,962 shares and € 744,017.58 on sales.

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

Retrieved on: 
Thursday, November 9, 2023
Webcast, Editorial, Safety, BLA, Month, DBV Technologies, Asthma, Risk, Database, Patient, OLE, FDA, American College, DBV, EST, Children's Hospital Colorado, Immunotherapy, Food allergy, ACAAI, Anaphylaxis, Pharmaceutical industry, Dietary supplement, Vaccine, Cryptocurrency, Wine, Silviculture, Euronext

Company to host investor conference call and webcast at 5:00pm ET today, Thursday, November 9th, to discuss the results.

Key Points: 
  • Company to host investor conference call and webcast at 5:00pm ET today, Thursday, November 9th, to discuss the results.
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive interim results from its ongoing Open-Label Extension (OLE) Study of EPITOPE (Phase 3 trial of Viaskin™ Peanut 250 µg [VP250] in toddlers ages 1 to 3 years), which is named EPOPEX.
  • After completing participation in the EPITOPE study, eligible subjects could enroll in EPOPEX to receive a total of three years of Viaskin Peanut treatment.
  • “We are thrilled with the results generated from the two-year open-label extension to the Phase 3 EPITOPE trial.

Aiolos Bio Strengthens and Expands Leadership Team with Key Appointments

Retrieved on: 
Tuesday, December 12, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, COPD, Atlas Venture, Entrepreneurship, DBV Technologies, Rockefeller University, Investment, PD, Respiratory system, Patient, Strategic planning, Element, Doctor of Philosophy, M&A, Galvani Bioelectronics, GSK, MedImmune, Caregiver, Atopic dermatitis, R, Publishing, Atlas, McKinsey & Company, Asthma, Pharmaceutical industry, Neuroscience, Aeolus, Genentech

“We are delighted to welcome René and Tapan as key members of our leadership team at this exciting time for the Company as we prepare to initiate a Phase 2 clinical trial for our lead drug candidate, AIO-001, in moderate-to-severe asthma patients,” said Khurem Farooq, Co-Founder and Chief Executive Officer of Aiolos Bio.

Key Points: 
  • “We are delighted to welcome René and Tapan as key members of our leadership team at this exciting time for the Company as we prepare to initiate a Phase 2 clinical trial for our lead drug candidate, AIO-001, in moderate-to-severe asthma patients,” said Khurem Farooq, Co-Founder and Chief Executive Officer of Aiolos Bio.
  • “I’m thrilled to be joining the talented team at Aiolos Bio,” said Dr. Van der Merwe.
  • We look forward to presenting and publishing data in 2024.” Dr. Van der Merwe will join Aiolos Bio effective January 2,2024.
  • He joins Aiolos Bio from Bain Capital Life Sciences where he led and managed investments across therapeutic areas.

DBV Technologies to Present New Data at ACAAI 2023

Retrieved on: 
Thursday, November 2, 2023
Aurora, Panel discussion, FDA, American College, DBV, Food, Biologics license application, ACAAI, Safety, European Medicines Agency, MBA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, PST, Immune system, Risk, Asthma, DRS, DBV Technologies, Allergy, Children's Hospital Colorado, Patient, BLA, Pharmaceutical industry, Vaccine, Euronext

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.
  • The presentation will be available on DBV’s website, www.dbv-technologies.com , following the conclusion of the meeting for those who are unable to attend.
  • In addition, DBV is a 2023 ACAAI Benefactor Level Corporate Council Member.
  • The Company will also host a booth in the ACAAI Exhibit Hall from Saturday, November 11 – Monday, November 13th.